Prices hovering near $4,500 are just the surface of a deeper story: institutions are hoarding ETH at record levels, staking […] The post Ethereum News: Institutional Buying, Staking Boom, and a $5,000 Target appeared first on Coindoo.Prices hovering near $4,500 are just the surface of a deeper story: institutions are hoarding ETH at record levels, staking […] The post Ethereum News: Institutional Buying, Staking Boom, and a $5,000 Target appeared first on Coindoo.

Ethereum News: Institutional Buying, Staking Boom, and a $5,000 Target

2025/09/13 19:35
3 min read
For feedback or concerns regarding this content, please contact us at [email protected]

Prices hovering near $4,500 are just the surface of a deeper story: institutions are hoarding ETH at record levels, staking is locking up massive amounts of supply, and smart contract activity has reached heights never seen before.

Institutions Take the Driver’s Seat

Corporate treasuries and investment funds have quietly transformed Ethereum into a core holding. Since April, fund-controlled reserves have more than doubled, reaching 6.5 million ETH. Whale wallets, defined as addresses with holdings between 10,000 and 100,000 ETH, now collectively manage more than 20 million coins.

The standout player in this race is BitMine. Originally a mining company, it has become the single largest corporate holder of Ethereum after a $201 million purchase in September lifted its treasury to over 2.1 million ETH, worth more than $9 billion. That one move has made BitMine a bellwether for institutional confidence in Ethereum’s future.

Locked Supply, Rising Demand

On the technical side, Ethereum’s proof-of-stake model is tightening supply faster than ever. More than 36 million ETH is staked, and the waiting queue to become a validator has ballooned past $3.6 billion. With coins leaving exchanges and entering long-term staking, analysts see a classic setup for a supply squeeze if buying continues.

A Network at Full Throttle

Activity on-chain tells the same story. Over 12 million daily smart contract calls are being recorded — a record that underlines Ethereum’s role as the backbone of decentralized finance, tokenized assets, and next-generation applications.

READ MORE:

Major Pi Network News: Big Developments You Can’t Ignore

This surge in use coincides with strong price action. Ethereum briefly touched an all-time high of $4,956 in late August before settling into the mid-$4,000s. With resistance pegged around $5,200 and declining inflows to exchanges, traders are eyeing the possibility of another breakout.

Bigger Vision Ahead

For Joseph Lubin, founder of ConsenSys, this is only the beginning. He envisions Ethereum evolving into the foundation of global finance, predicting Wall Street adoption could multiply its value a hundredfold. That outlook suggests Ethereum could eventually challenge Bitcoin’s dominance as a monetary base.

The combination of institutional buying, aggressive staking, shrinking exchange reserves, and soaring on-chain activity has created a perfect storm for Ethereum in 2025. Whether ETH crosses $5,000 soon or consolidates first, the bigger trend is clear: Ethereum is no longer just another blockchain — it is being positioned as a central pillar of the financial system itself.


The information provided in this article is for educational purposes only and does not constitute financial, investment, or trading advice. Coindoo.com does not endorse or recommend any specific investment strategy or cryptocurrency. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.

The post Ethereum News: Institutional Buying, Staking Boom, and a $5,000 Target appeared first on Coindoo.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09